U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 11 - 20 of 2721 results

Amdoxovir is a guanosine analogue nucleoside reverse transcriptase inhibitor that is active in vitro against both HIV-1 and HBV. It is deaminated intracellularly by adenosine deaminase to dioxolane guanine (DXG). DXG-triphosphate, the active form of the drug, has greater activity than DAPD-triphosphate. Amdoxovir is under development (phase II study) for the treatment of HIV infection. Five subjects demonstrated lens opacities during the study, although baseline evaluations were not performed. Clinical studies of amdoxovir are currently on hold pending additional safety data.
Status:
Investigational
Source:
NCT04349072: Phase 3 Interventional Recruiting HOCM, Hypertrophic Obstructive Cardiomyopathy
(2020)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Targets:

MYK-461 (also known as Mavacamten) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy, one of the most prevalent heritable cardiovascular disorders. Studies on isolated cells and muscle fibers, as well as intact animals, have shown that MYK-461 inhibits sarcomere force production, thereby reducing cardiac contractility. In Phase II clinical trials MYK-461 reduces left ventricular outflow tract obstruction and improve exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy. Phase III clinical trials are currently ongoing.
Status:
Investigational
Source:
NCT00815763: Phase 3 Interventional Completed Ischemic Stroke
(2006)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Status:
Investigational
Source:
NCT02903836: Phase 2 Interventional Completed Community-Acquired Bacterial Pneumonia (CABP)
(2016)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:MIVAZEROL [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Mivazerol is a new and selective alpha 2-adrenoceptor agonist, devoid of hypotensive effects, which has been designed to prevent adverse cardiac outcome in perioperative patients with, or at risk coronary artery disease. This compound, which lacks hypotensive effects, has been demonstrated to prevent hyperadrenergic activity and myocardial ischemia in perioperative patients and tachycardia in rats at emergence from halothane anesthesia. This type of ischemia, frequently encountered in postoperative patients, is considered to be a consequence of stress-induced hyperactivation of the sympathetic system. Anti-ischemic effects of this compound have been demonstrated in different animal models of myocardial ischemia, and Mivazerol has also been shown to improve exercise-induced ischemia in patients with angina pectoris.
Status:
Investigational
Source:
INN:basifungin
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Basifungin, previously known as LY 295337 or aureuobacidin A, is an antifungal agent that inhibits phosphorylceramide synthase. The development of basifungin against mycoses was discontinued.
Status:
Investigational
Source:
INN:maroxepin
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Maroxepin is a tetracyclic compound antagonizing activity of dopamine receptors. Maroxepin has a potent central nervous action and a strong sedative potential. Maroxepin exerts both antipsychotic and antidepressant properties.
Status:
Investigational
Source:
INN:oxabrexine
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Oxabrexine was developed as a diuretic; however, this compound has never been marketed. Information about the current use of this compound is not available.
Status:
Investigational
Source:
INN:flutemazepam
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Flutemazepam is a benzodiazepine binding-site agonist and has hypnotic, anticonvulsant and anxiolytic activity. Flutemazepam was found very effective for the treatment of severe states of anxiety
Status:
Investigational
Source:
NCT04688580: Early Phase 1 Interventional Recruiting Healthy
(2020)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Showing 11 - 20 of 2721 results